P. Ulrichts

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

R. Ober, E. Ward, P. Verheesen, 2018, The Journal of clinical investigation.

ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome

M. Huijbers, Roy Augustinus, Julien Oury, 2024, Science Translational Medicine.

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

H. de Haard, A. Newland, M. Michel, 2019, American journal of hematology.